Bayer's $7.25 Billion Settlement: A New Chapter in Roundup Litigation?

Bayer's Monsanto proposes a $7.25 billion settlement to resolve Roundup cancer claims. This settlement seeks to address both existing and future lawsuits over non-Hodgkin lymphoma allegedly caused by Roundup. Approval depends on adequate plaintiff support and pending a significant U.S. Supreme Court decision on related state law claims.

Bayer's Monsanto unit has announced a substantial $7.25 billion settlement aimed at concluding ongoing and future litigation concerning its controversial Roundup weedkiller, alleged to cause cancer.

Under the proposal, the settlement would distribute payments over 21 years to those claiming Roundup exposure resulted in non-Hodgkin lymphoma. However, the deal's approval hinges on significant plaintiff support and the outcome of Bayer's U.S. Supreme Court case.

The settlement includes a long-term claims program and does not guarantee closure, as plaintiffs have the option to opt out and litigate individually. The U.S. Supreme Court's ruling could further impact the viability of these claims.